local_hospital

Sismanogleio General Hospital

Address
Sismanogliou 37, 151 26 Athens, Greece

Sismanogleio General Hospital - Clinical Research Center

Sismanogleio General Hospital serves as an active clinical research center with expertise spanning ophthalmology and infectious disease management. The facility conducts pivotal trials evaluating innovative therapeutic approaches and diagnostic strategies aimed at improving patient outcomes across diverse medical conditions.

  • Ophthalmology research focusing on glaucoma and ocular hypertension treatment modalities
  • Infectious disease management including community-acquired pneumonia and sepsis prevention strategies
  • Biomarker-guided therapy and precision medicine approaches for severe infections

The center's research portfolio includes comparative effectiveness studies of fixed-combination eye drops for elevated intraocular pressure management, as well as groundbreaking work in procalcitonin-guided antibiotic therapy and molecular diagnostics to optimize antimicrobial stewardship. Their infectious disease research emphasizes early intervention strategies using biomarker-guided treatment protocols, particularly exploring the role of adjunctive clarithromycin therapy in preventing sepsis progression in high-risk pneumonia patients.

Site Overview

assignment
10
connected trials
corporate_fare
6
sponsors
science
28
IMPs

Activity Indicator

Last 6 months

1
Trials started
-50% vs previous period.
2
Trials started 6–12 months ago
10
Total trials linked
Highly Active
trending_downDeclining-50%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 6 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
5
Sponsors (total)
6
Active sponsors
5

Sponsor Network

Top 5 by active trials.

lock +4 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 173 other sites in Greece

description
Trial volume
10
Outperforms 66% of sites
public
Therapeutic diversity
6areas
Outperforms 74% of sites
groups
Sponsor diversity
6sponsors
Outperforms 64% of sites

Therapeutic Area Benchmark — Greece

Select a therapeutic area to compare against other sites in Greece.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Greece

Market Share

Country: Greece

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Sismanogleio General Hospital

lock Showing 1 of 10 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 28 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Ziltivekimab2Unknown2024-03-272024-08-01

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.